Referencia número: HY-13735

Quinacrine

Name: Quinacrine
Brand: MedChemExpress
SKU: HY-13735
Price: 35.00 USD
Availability: InStock
Rating: 5 (9 reviews)

(Synonyms: Acriquine)

9 Cited Publications

Revisión del cliente

Based on 9 publication(s) in Google Scholar

Quinacrine (Acriquine) is an antimalarial and anti-cancer agent. Quinacrine also inhibits human aldehyde oxidase (IC₅₀: 3.3 μM). Quinacrine has affinity for nucleic acids, and stains DNA and RNA in fixed cells (Ex/Em: 436/525 nm).

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 98.20%
No. CAS: 83-89-6
Fòrmula: C₂₃H₃₀ClN₃O
Peso molecular:399.96

Almacenamiento:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Quinacrine Chemical Structure

No. CAS: 83-89-6

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (9)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Ver todos los productos específicos de isoformas Parasite :

Ver todos los productos específicos de isoformas Sodium Channel :

Ver todos los productos específicos de isoformas Aldehyde Oxidase (AO) :

AOX1

Cellular Effect

Cell Line	Type	Value	Description	References
184B5	IC₅₀	4.96 μM Compound: QC	Cytotoxicity against human 184B5 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human 184B5 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28586716]
184B5	IC₅₀	4.96 μM Compound: Quinacrine	Antiproliferative activity against human 184B5 cells after 48 hrs by SRB assay Antiproliferative activity against human 184B5 cells after 48 hrs by SRB assay	[PMID: 29232580]
BHK-21	CC₅₀	18.59 μM Compound: 40	Cytotoxicity against BHK21 cells after 24 to 48 hrs by CCK8 assay Cytotoxicity against BHK21 cells after 24 to 48 hrs by CCK8 assay	[PMID: 31549836]
BHK-21	CC₅₀	19.8 μM Compound: 18	Cytotoxicity against hamster BHK-21 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against hamster BHK-21 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 36940609]
CHO-AA8	IC₅₀	1.7 μM Compound: 4 (quinacrine mustard)	In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8 In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8	[PMID: 2319563]
HeLa	IC₅₀	1.05 μM Compound: Quinacrine	Antiviral activity against Ebolavirus infected in human HeLa cells assessed as reduction in viral replication incubated for 48 hrs by luminescence based assay Antiviral activity against Ebolavirus infected in human HeLa cells assessed as reduction in viral replication incubated for 48 hrs by luminescence based assay	[PMID: 32832035]
Hepatocyte	IC₅₀	73 μM Compound: 9 Quinacrine	Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes	[PMID: 15225721]
Hepatocyte	IC₅₀	3 x 10⁴ nM Compound: Quinacrine	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
HepG2	CC₅₀	9.78 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells after 48 hrs by Alamar Blue assay Cytotoxicity against human HepG2 cells after 48 hrs by Alamar Blue assay	[PMID: 24354316]
HepG2	EC₅₀	11.9 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 27788467]
HepG2	EC₅₀	10.44 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by Alamar blue assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by Alamar blue assay	[PMID: 27992217]
HepG2	EC₅₀	10.44 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells after 48 hrs by Alamar Blue-based assay Cytotoxicity against human HepG2 cells after 48 hrs by Alamar Blue-based assay	[PMID: 28740614]
HepG2	EC₅₀	7653.7 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells after 48 hrs by alamar blue assay Cytotoxicity against human HepG2 cells after 48 hrs by alamar blue assay	[PMID: 30655955]
HepG2	CC₅₀	7.6 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay	[PMID: 33479683]
HT-1080	IC₅₀	29 μM Compound: Quinacrine	Anticancer activity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
HT-22	EC₅₀	9.09 μM Compound: Quinacrine	Cytotoxicity against mouse HT22 cells after 24 hrs by MTT assay Cytotoxicity against mouse HT22 cells after 24 hrs by MTT assay	[PMID: 24602904]
HT-29	IC₅₀	55 μM Compound: Quinacrine	Concentration required to inhibit colony formation by 50% in human colon carcinoma HT-29 cells Concentration required to inhibit colony formation by 50% in human colon carcinoma HT-29 cells	[PMID: 8289202]
Huh-7	CC₅₀	19.61 μM Compound: GNF-Pf-5448	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
Mast cell	IC₅₀	13.7 μM Compound: Mepacrine	Inhibition of compound 48/80-stimulated beta-glucuronidase release in rat peritoneal mast cell Inhibition of compound 48/80-stimulated beta-glucuronidase release in rat peritoneal mast cell	[PMID: 15568764]
Mast cell	IC₅₀	23.3 μM Compound: Mepacrine	Inhibition of compound 48/80-stimulated histamine release in rat mast cell Inhibition of compound 48/80-stimulated histamine release in rat mast cell	[PMID: 15568764]
MCF7	IC₅₀	4.19 μM Compound: QC	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28586716]
MCF7	IC₅₀	4.19 μM Compound: Quinacrine	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 29232580]
MCF7	IC₅₀	7.5 μM Compound: Quinacrine	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30684866]
MDA-MB-231	IC₅₀	3.25 μM Compound: QC	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28586716]
MDA-MB-231	IC₅₀	3.25 μM Compound: Quinacrine	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 29232580]
MDA-MB-468	IC₅₀	3.96 μM Compound: QC	Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28586716]
MDA-MB-468	IC₅₀	3.96 μM Compound: Quinacrine	Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by SRB assay	[PMID: 29232580]
N2a #58 F3	EC₅₀	1.88 μM Compound: quinacrine	Antiprion activity against human prion Fukuoka-1 infected mouse F3 cells assessed as reduction of scrapie prion protein accumulation Antiprion activity against human prion Fukuoka-1 infected mouse F3 cells assessed as reduction of scrapie prion protein accumulation	[PMID: 18556207]
N2a #58 F3	EC₅₀	1.88 μM Compound: Quinacrine	Antiprion activity against human prion protein Fukuoka-1 infected mouse F3 cells assessed as reduction of PrPSc level by Western blot method Antiprion activity against human prion protein Fukuoka-1 infected mouse F3 cells assessed as reduction of PrPSc level by Western blot method	[PMID: 21531054]
ScN2a	EC₅₀	0.3 μM Compound: Quinacrine	Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells	[PMID: 12904059]
ScN2a	EC₅₀	0.5 μM Compound: 1	Inhibition of PrPSc accumulation in mouse ScN2a cell line relative to control Inhibition of PrPSc accumulation in mouse ScN2a cell line relative to control	[PMID: 16860557]
ScN2a	EC₅₀	300 nM Compound: quinacrine	Inhibition of protease-resistant scrapie prion protein activity in ScN2a cells Inhibition of protease-resistant scrapie prion protein activity in ScN2a cells	[PMID: 17064077]
ScN2a	EC₅₀	0.8 μM Compound: quinacrine	Reduction of PrPSC accumulation in ScN2a cells Reduction of PrPSC accumulation in ScN2a cells	[PMID: 17201410]
ScN2a	EC₅₀	0.23 μM Compound: quinacrine	Antiprion activity against scrapie prion protein RML infected mouse ScN2a cells assessed as reduction of scrapie prion protein accumulation by immunoblot analysis Antiprion activity against scrapie prion protein RML infected mouse ScN2a cells assessed as reduction of scrapie prion protein accumulation by immunoblot analysis	[PMID: 18556207]
ScN2a	EC₅₀	0.3 μM Compound: Quinacrine	Antiprion activity against Scrapie prion protein-mediated scrapie in RML mouse ScN2a cells assessed as reduction of PrP-Sc level after 6 days by immunoblotting Antiprion activity against Scrapie prion protein-mediated scrapie in RML mouse ScN2a cells assessed as reduction of PrP-Sc level after 6 days by immunoblotting	[PMID: 19842664]
ScN2a	EC₅₀	0.23 μM Compound: Quinacrine	Antiprion activity against mouse prion protein RML infected mouse ScN2a cells assessed as reduction of PrPSc level by Western blot method Antiprion activity against mouse prion protein RML infected mouse ScN2a cells assessed as reduction of PrPSc level by Western blot method	[PMID: 21531054]
SH-SY5Y	IC₅₀	8.57 μM Compound: Quinacrine	Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
U-251	IC₅₀	5 μM Compound: 81	Antiproliferative activity against human U251 cells by MTT assay Antiproliferative activity against human U251 cells by MTT assay	[PMID: 30583248]
U2OS	EC₅₀	0.25 μM Compound: 157	Inhibition of autophagy in human U2OS cells expressing tfLC3 incubated for 3 hrs by fluorescent microscopy Inhibition of autophagy in human U2OS cells expressing tfLC3 incubated for 3 hrs by fluorescent microscopy	[PMID: 36283182]
U2OS	IC₅₀	2.5 μM Compound: 157	Cytotoxicity against human U2OS cells Cytotoxicity against human U2OS cells	[PMID: 36283182]
UV4	IC₅₀	0.14 μM Compound: 4 (quinacrine mustard)	In vitro cytotoxicity against transformed chinese hamster fibroblast line UV4. In vitro cytotoxicity against transformed chinese hamster fibroblast line UV4.	[PMID: 2319563]
Ventricular myocyte	IC₅₀	5.2 μM Compound: Mepacrine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]
Vero	EC₅₀	2.27 μM Compound: 40	Antiviral activity against Zika virus MR766 infected in African green monkey Vero cells by plaque assay Antiviral activity against Zika virus MR766 infected in African green monkey Vero cells by plaque assay	[PMID: 31549836]
Vero	CC₅₀	14.71 μM Compound: Quinacrine	Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr	10.1101/2020.03.20.999730
Vero	IC₅₀	>50 μM Compound: Quinacrine	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr	10.1101/2020.03.20.999730
WIL2-NS	CC₅₀	4.8 μM Compound: Quinacrine	Cytotoxicity against human WIL2-NS cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay Cytotoxicity against human WIL2-NS cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay	[PMID: 33479683]

In Vitro

Quinacrine inhibits human and rabbit aldehyde oxidase, with IC₅₀s of 3.3 μM and 10 μM respectively^[2].
Quinacrine blocks voltage-dependent sodium channels (IC₅₀: 3.3 μM)^[3].
Quinacrine (100 μM) is also a PLA2 inhibitor^[4].
Quinacrine (0-20 μM, 24 h) inhibits the growth of SGC-7901 cells, and induces cell apoptosis^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[7]

Cell Line:

SGC-7901 cell
Concentration:

0, 5, 10, 15, 20 μM
Incubation Time:

24 h
Result:

Inhibited cell growth with an IC₅₀ value of 16.18 μM.

In Vivo

Quinacrine (3-30 mg/kg, i.p., once daily for three days) has protective effect against glycerol-induced acute kidney injury in rats^[5].
Quinacrine (2.5-10 mg/kg, i.p., once daily for eight weeks) has protective effect against Cyclosporine-induced nephrotoxicity in rats^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Acute kidney injury rat model^[5]
Dosage:

3-30 mg/kg
Administration:

i.p.
Result:

Attenuated glycerol induced structural and functional changes in kidney.

Chemical Information

No. CAS 83-89-6
Appearance Oil
Peso molecular 399.96
Fòrmula C₂₃H₃₀ClN₃O
Color Light yellow to yellow
SMILES

CC(CCCN(CC)CC)NC1=C2C=C(C=CC2=NC3=CC(Cl)=CC=C31)OC
Synonyms

Acriquine
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (9)

All Bio/Physico-chemical AssayCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

J Biomed Sci

Targeting the G-quadruplex as a novel strategy for developing antibiotics against hypervirulent drug-resistant Staphylococcus aureus. [Abstract]

2025 Feb 5;32(1):15. PMID: 39905515

Quinacrine purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2025 Feb 5;32(1):15. [Abstract]

The tabulated datasheet from IC₅₀ data showing the percent inhibition of SAUSA300 cells at 10 µM of G4-ligands (Quinacrine dihydrochloride, etc.) and their IC₅₀ values.
J Neuroinflammation

STING activates ZBP1-mediated PANoptosis to defend against HSV-1 retinal infection. [Abstract]

2025 Oct 27;22(1):243. PMID: 41146204
Phytomedicine

Quinacrine induces autophagy via the Dlg5/AKT pathway to inhibit osteosarcoma cell proliferation and suppresses migration and invasion through the Dlg5/Girdin pathway. [Abstract]

2025 Sep:145:156981. PMID: 40541124
J Pharm Anal

2025 Dec 15.
Part Fibre Toxicol

Exposure to high dose of polystyrene nanoplastics causes trophoblast cell apoptosis and induces miscarriage. [Abstract]

2024 Mar 7;21(1):13. PMID: 38454452

Quinacrine purchased from MedChemExpress. Usage Cited in: Part Fibre Toxicol. 2024 Mar 7;21(1):13. [Abstract]

Cell viability of trophoblast cells treated with 10 μM Raptinal, 15 μM Quinacrine dihydrochloride, or 500 μg/mL PS-NPs, and co-treated with 10 μM Z-VAD-FMK for 48 h. The results showed that treatment with Raptinal, Quinacrine dihydrochloride, or PS-NPs reduced trophoblast cell viability, and co-treatment with Z-VAD-FMK rescued trophoblast cell viability.
Brain Behav Immun

Inhibition of the NFATc2/FKBP5 axis alleviates microglial neuroinflammation by regulating arachidonic acid metabolism in Parkinson's disease. [Abstract]

2026 Jan 18:134:106296. PMID: 41554345
Pharmaceutics

Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets. [Abstract]

2022 Jan 12;14(1):176. PMID: 35057070

Quinacrine purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2022 Jan 12;14(1):176. [Abstract]

Quinacrine (Mepacrine) dihydrochloride inhibited the enzymatic activities of TMPRSS2 and PL^pro, with IC₅₀ values of 29.9 μM and 4.4 μM, respectively.
bioRxiv

2025 Nov 11.
University of Saskatchewan

2020 Jun 22.

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (125.01 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5003 mL

12.5013 mL

25.0025 mL

5 mM

0.5001 mL

2.5003 mL

5.0005 mL

10 mM

0.2500 mL

1.2501 mL

2.5003 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (12.50 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (281 KB)
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Korean - KR (558 KB)
- Portuguese - PT (558 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Vogtherr M, et al. Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem. 2003 Aug 14;46(17):3563-4. [Content Brief]

[2]. Pryde DC, et al. Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem. 2010 Dec 23;53(24):8441-60. [Content Brief]

[3]. McNeal ET, et al. [3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs. J Med Chem. 1985 Mar;28(3):381-8. [Content Brief]

[4]. Caro AA,et al. Role of phospholipase A2 activation and calcium in CYP2E1-dependent toxicity in HepG2 cells. J Biol Chem. 2003 Sep 5;278(36):33866-77. [Content Brief]

[5]. Al Asmari AK, et al. Protective effect of quinacrine against glycerol-induced acute kidney injury in rats. BMC Nephrol. 2017 Jan 28;18(1):41. [Content Brief]

[6]. al Khader A, et al. Quinacrine attenuates cyclosporine-induced nephrotoxicity in rats. Transplantation. 1996 Aug 27;62(4):427-35. [Content Brief]

[7]. Wu X, et al. Quinacrine Inhibits Cell Growth and Induces Apoptosis in Human Gastric Cancer Cell Line SGC-7901. Curr Ther Res Clin Exp. 2012 Feb;73(1-2):52-64. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5003 mL	12.5013 mL	25.0025 mL	62.5063 mL
	5 mM	0.5001 mL	2.5003 mL	5.0005 mL	12.5013 mL
	10 mM	0.2500 mL	1.2501 mL	2.5003 mL	6.2506 mL
	15 mM	0.1667 mL	0.8334 mL	1.6668 mL	4.1671 mL
	20 mM	0.1250 mL	0.6251 mL	1.2501 mL	3.1253 mL
	25 mM	0.1000 mL	0.5001 mL	1.0001 mL	2.5003 mL
	30 mM	0.0833 mL	0.4167 mL	0.8334 mL	2.0835 mL
	40 mM	0.0625 mL	0.3125 mL	0.6251 mL	1.5627 mL
	50 mM	0.0500 mL	0.2500 mL	0.5001 mL	1.2501 mL
	60 mM	0.0417 mL	0.2084 mL	0.4167 mL	1.0418 mL
	80 mM	0.0313 mL	0.1563 mL	0.3125 mL	0.7813 mL
	100 mM	0.0250 mL	0.1250 mL	0.2500 mL	0.6251 mL

Bioz

Keywords

Quinacrine

9 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Quinacrine

Publications Citing Use of MedChemExpress (MCE) Quinacrine

Ver todos los productos específicos de isoformas Parasite

Ver todos los productos específicos de isoformas Sodium Channel

Ver todos los productos específicos de isoformas Aldehyde Oxidase (AO)